Sivakumar S M, Sukumaran N, Murugesan R, Shanmugarajan T S, Anbu J, Sivakumar L, Anilbabu B, Srinivasarao G, Ravichandran V
Vel's College of Pharmacy, Pallavaram, Chennai-600 117, India.
Indian J Pharm Sci. 2008 Jul-Aug;70(4):487-90. doi: 10.4103/0250-474X.44599.
The present study was aimed to replace the alum type adjuvant for hepatitis B vaccine. The hepatitis B vaccine was encapsulated in poly (DL-lactide-co-glycolide) microspheres by solvent evaporation technique. The formulated microspheres were characterized in terms of morphology, particle size analysis, in vitro release study and in vivo immune response in male Wistar rats. The FT IR spectrum illustrates the characteristics bands of poly (DL-lactide-co-glycolide) microspheres and hepatitis B vaccine at 1750 cm(-1) and 1650 cm(-1), respectively. The hepatitis B vaccine loaded poly (DL-lactide-co-glycolide) microspheres were able to release antigens till day 42. Significant enhancement of specific antibodies to HBsAg was produced till day 90 after a single administration of HBsAg encapsulated poly (DL-lactide-co-glycolide) microspheres. However, the conventional alum adsorbed hepatitis B vaccine was not found to produce any significant specific antibody levels till day 90 after a single dose. The results showed that poly (DL-lactide-co-glycolide) microspheres show potential as an adjuvant for hepatitis B vaccine.
本研究旨在寻找可替代乙肝疫苗中明矾类佐剂的物质。采用溶剂蒸发技术将乙肝疫苗包裹于聚(DL-丙交酯-共-乙交酯)微球中。对制备的微球进行了形态学、粒径分析、体外释放研究以及在雄性Wistar大鼠体内的免疫反应研究。傅里叶变换红外光谱(FT IR)显示,聚(DL-丙交酯-共-乙交酯)微球和乙肝疫苗的特征峰分别位于1750 cm(-1)和1650 cm(-1)处。负载乙肝疫苗的聚(DL-丙交酯-共-乙交酯)微球能够在42天内持续释放抗原。单次注射包裹乙肝表面抗原(HBsAg)的聚(DL-丙交酯-共-乙交酯)微球后,直至第90天,针对HBsAg的特异性抗体显著增强。然而,传统的明矾吸附型乙肝疫苗在单次注射后直至第90天未发现产生任何显著的特异性抗体水平。结果表明,聚(DL-丙交酯-共-乙交酯)微球有望作为乙肝疫苗的佐剂。